- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07942402
Impact of Preoperative Urine Culture Following Transurethral Resection of the Prostate (UROCULTURP). (UROCULTURP)
Impact of Preoperative Urine Culture on the Prevention of Postoperative Urinary Tract Infections Following Transurethral Resection of the Prostate in Men With Benign Prostatic Hyperplasia: Protocol for a Multicenter, Parallel-group, Randomized Non-inferiority Diagnostic Test Trial.
Benign prostatic hyperplasia (BPH) is a common condition in men, and a proportion of affected patients require surgical treatment. Transurethral resection of the prostate (TURP) is considered the gold standard for the surgical management of these patients. Preoperative asymptomatic bacteriuria (ASB) is present in approximately 30% of patients with BPH undergoing TURP. Current guidelines recommend screening for and treating ASB before endoscopic urological procedures associated with mucosal trauma to prevent postoperative infectious complications. However, the precise role of ASB in the development of postoperative urinary tract infections (UTIs) remains unclear, and the quality of the evidence supporting these recommendations is low.
A prospective, comparative clinical study is therefore warranted to determine the effectiveness of preoperative screening for and treatment of ASB in preventing infectious complications in patients with BPH undergoing TURP. The findings may help address existing knowledge gaps, inform future recommendations, and promote adherence to evidence-based clinical decision-making.
The objective of this study is to determine the effectiveness of preoperative screening for and treatment of ASB in preventing postoperative infectious complications in patients with BPH undergoing TURP.
A multicenter, parallel-group, randomized non-inferiority diagnostic test trial is proposed. A total of 1,262 men aged over 45 years with a diagnosis of BPH, an indication for TURP due to BPH, and no signs or symptoms of UTI will be enrolled. Participants will be randomly assigned in a 1:1 ratio to one of two groups according to whether the results of the preoperative urine culture are disclosed or withheld. Participants will be followed up for one month, and the primary outcome will be the occurrence of urinary tract infection (UTI).
The study was approved for review by the Research Ethics Committee of the Faculty of Medicine at the University of Antioquia and by the ethics committees of all participating institutions involved in patient recruitment.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Francisco L Caro, MD, Urologist
- Numéro de téléphone: +57 604-219-8332
- E-mail: francisco.caro@udea.edu.co
Sauvegarde des contacts de l'étude
- Nom: Ivan D Florez, MD, MSc, PhD
- Numéro de téléphone: +57 313 7421132
- E-mail: ivan.florez@udea.edu.co
Lieux d'étude
-
-
Antioquia
-
Medellín, Antioquia, Colombie
- Hospital Alma Mater de Antioquia
-
Contact:
- Deimer E Mercado, MD, Urologist
- Numéro de téléphone: +57 604-219-6940
- E-mail: deimer.mercado@udea.edu.co
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Men aged >45 years with a diagnosis of benign prostatic hyperplasia (BPH).
- Indication for transurethral resection of the prostate (TURP) for BPH.
- Absence of signs or symptoms of urinary tract infection (UTI).
Exclusion Criteria:
- Symptomatic urinary tract infection (UTI) or antibiotic treatment within the previous month for a UTI or any other infectious condition.
- Patients scheduled to undergo additional transurethral procedures during the same surgical session (e.g., urethrotomy, transurethral resection of a bladder tumor [TURBT], or cystolithotomy).
- Diagnosis of prostate cancer.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Disclosure Group
Disclosure of preoperative urine culture results |
In this arm, the results of the preoperative urine culture will be made available to the treating urologist. |
|
Autre: Non-Disclosure Group
Non-disclosure of preoperative urine culture results |
In this arm, the results of the preoperative urine culture will not be made available to the treating urologist. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Urinary tract infection (UTI)
Délai: 30 days or 1 month
|
UTI was defined according to the American Urological Association (AUA) antimicrobial prophylaxis guidelines (43), supplemented by the European Association of Urology (EAU) UTI diagnostic criteria (10). Patients were classified as having a UTI if they met any of 4 scenarios: (1) ≥1 urinary symptom or fever, positive urine culture (>10⁵ CFU), and surgeon-confirmed post-endoscopic UTI; (2) ≥2 urinary symptoms or fever plus supportive laboratory findings or clinical diagnosis; (3) postoperative fever with imaging suggestive of pyelonephritis after TURP, or catheter-associated UTI with ≥10³ CFU/mL within the specified catheterization period; or (4) ≥2 persistent urinary symptoms for >1 week after catheter removal, without fever or improvement, plus positive urine culture (>10⁵ CFU) and surgeon-confirmed post-endoscopic UTI. |
30 days or 1 month
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Urinary sepsis
Délai: 30 days or 1 month
|
Patients will be diagnosed with rrinary sepsis if they meet the criteria:
In clinical practice, organ dysfunction may be indicated by a Quick Sequential Organ Failure Assessment (qSOFA) score of ≥2. The qSOFA criteria are a respiratory rate of ≥22 breaths/min, altered mental status, or systolic blood pressure of ≤100mmHg. Septic shock will be defined as the requirement for vasopressors to maintain a mean arterial pressure of ≥65 mmHg, together with a serum lactate level of >2 mmol/L(>18 mg/dL), in the absence of hypovolemia |
30 days or 1 month
|
|
Acute orchiepididymitis
Délai: 30 days or 1 month
|
Acute orchiepididymitis will be defined as the presence of scrotal pain, swelling, increased temperature, and inflammatory changes, accompanied by testicular and/or epididymal tenderness and enlargement on palpation; or inflammatory changes involving the testis and/or epididymis, with increased blood flow on color Doppler ultrasonography, with or without intratesticular collections on ultrasound examination. These findings may occur regardless of whether the urine culture is positive. |
30 days or 1 month
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Francisco L Caro, MD, Urologist, Universidad de Antioquia
- Directeur d'études: Ivan D Florez, MD, MSc, PhD, Universidad de Antioquia
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Maladies génitales, sexe masculin
- Maladies de la prostate
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Infections
- Hyperplasie prostatique
- Infections des voies urinaires
Autres numéros d'identification d'étude
- SIIU2024-78410
- IN70-2024 (Autre identifiant: Hospital Alma Mater de Antioquia)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .